BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.

BMS announced data from the Phase III COMMANDS trial of Reblozyl • Source: Shutterstock

Reblozyl (luspatercept-aamt), which Bristol Myers Squibb Company is developing in later stages under a licensing agreement with Merck & Co., Inc., stands to greatly expand the addressable population with lower-risk myelodysplastic syndromes (MDS) with positive Phase III topline results from the COMMANDS trial, even as questions remain about the drug’s durability. The potential for a US label expansion into the first-line setting from the currently approved second-line setting could also help make up for a missed opportunity earlier this year in beta-thalassemia.

While not disclosing data, BMS said 31 October that COMMANDS met its primary endpoint, showing a highly statistically significant and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D